Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015;13(4):433-40.
doi: 10.2174/1570161112666141014144829.

Phenomics of Vascular Disease: The Systematic Approach to the Combination Therapy

Affiliations
Review

Phenomics of Vascular Disease: The Systematic Approach to the Combination Therapy

Yeshan Han et al. Curr Vasc Pharmacol. 2015.

Abstract

Vascular diseases are usually caused by multifactorial pathogeneses involving genetic and environmental factors. Our current understanding of vascular disease is, however, based on the focused genotype/phenotype studies driven by the "one-gene/one-phenotype" hypothesis. Drugs with "pure target" at individual molecules involved in the pathophysiological pathways are the mainstream of current clinical treatments and the basis of combination therapy of vascular diseases. Recently, the combination of genomics, proteomics, and metabolomics has unraveled the etiology and pathophysiology of vascular disease in a big-data fashion and also revealed unmatched relationships between the omic variability and the much narrower definition of various clinical phenotypes of vascular disease in individual patients. Here, we introduce the phenomics strategy that will change the conventional focused phenotype/genotype/genome study to a new systematic phenome/genome/proteome approach to the understanding of pathophysiology and combination therapy of vascular disease. A phenome is the sum total of an organism's phenotypic traits that signify the expression of genome and specific environmental influence. Phenomics is the study of phenome to quantitatively correlate complex traits to variability not only in genome, but also in transcriptome, proteome, metabolome, interactome, and environmental factors by exploring the systems biology that links the genomic and phenomic spaces. The application of phenomics and the phenome-wide associated study (PheWAS) will not only identify a systemically-integrated set of biomarkers for diagnosis and prognosis of vascular disease but also provide novel treatment targets for combination therapy and thus make a revolutionary paradigm shift in the clinical treatment of these devastating diseases.

PubMed Disclaimer

Conflict of interest statement

The authors confirm that this article content has no conflict of interest.

Figures

Fig. (1)
Fig. (1)
Schematic description of contributions from the interplay between genetic and environmental factors to the development of vascular disease and the role of relative biomarkers in clinical vascular disease phenotypes
Fig. (2)
Fig. (2)
Genetic study of phenotype-genotype association.
Fig. (3)
Fig. (3)
Omic study of phenotype-genotype association.
Fig. (4)
Fig. (4)
Phenomics approach to the definition of clinical phenome of vascular disease and the identification of multiple drug targets suitable for personalized therapy.
Fig. (5)
Fig. (5)
An iceberg model of the relationship of phenomics with other omics approaches and platforms in translational research on personalized medicine.

Similar articles

Cited by

References

    1. Iacoviello L., Donati M.B. Gene-environment interactions: implications for cardiovascular disease. Cardiologia. 1999;44:227–232. - PubMed
    1. Moxon J.V., Padula M.P., Herbert B.R., Golledge J. Challenges, current status and future perspectives of proteomics in improving understanding, diagnosis and treatment of vascular disease. Eur. J. Vasc. Endovasc. Surg. 2009;38:346–355. - PMC - PubMed
    1. Nordon I., Brar R., Hinchliffe R., Cockerill G., Loftus I., Thompson M. The role of proteomic research in vascular disease. J. Vasc. Surg. 2009;49:1602–1612. - PubMed
    1. Rafter N., Connor J., Hall J., et al. Cardiovascular medications in primary care: treatment gaps and targeting by absolute risk. N. Z. Med. J. 2005;118:U1676. - PubMed
    1. Weir M.R. Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade. J. Hum. Hypertens. 2007;21:770–779. - PubMed

Publication types